Einloggen

Thematische Bibliographien / Hypertension portopulmonaire / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Hypertension portopulmonaire.

Zeitschriftenartikel zum Thema „Hypertension portopulmonaire“

Autor: Grafiati

Veröffentlicht am 25. Januar 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Hypertension portopulmonaire" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Chabot, F., E. Gomez, L. Boyer, A. Kheir, J. Le Pavec, O. Sitbon und P. Herve. „Hypertension portopulmonaire“. Revue des Maladies Respiratoires 23, Nr. 6 (Dezember 2006): 629–41. http://dx.doi.org/10.1016/s0761-8425(06)72078-2.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Magois, E., J. C. Glerant, I. Mayeux, B. Toublanc, D. Mispelaere und V. Jounieaux. „134 Hypertension artérielle portopulmonaire (HTTP) et opacités pseudotumorales“. Revue des Maladies Respiratoires 21 (Januar 2004): 61. http://dx.doi.org/10.1016/s0761-8425(04)71760-x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Halim, A., A. O. Daher, M. N. Guèye, S. Diallo, M. Bodian, M. P. Fall, M. A. Thioubou, M. L. Bassène, S. Fall und M. L. Diouf. „Hypertension portopulmonaire révélant une cirrhose d’origine auto-immune : à propos d’un cas“. Journal Africain d'Hépato-Gastroentérologie 10, Nr. 4 (16.09.2016): 217–19. http://dx.doi.org/10.1007/s12157-016-0677-1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Saleemi, Sarfraz. „Portopulmonary hypertension“. Annals of Thoracic Medicine 5, Nr. 1 (2010): 5. http://dx.doi.org/10.4103/1817-1737.58953.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Hopps, Eugenia, Amelia Valenti und Gregorio Caimi. „Portopulmonary Hypertension“. Clinical & Investigative Medicine 34, Nr. 3 (01.06.2011): 111. http://dx.doi.org/10.25011/cim.v34i3.15182.

Der volle Inhalt der Quelle

Annotation:

Portopulmonary hypertension (PPHT) is a respiratory complication of portal hypertension, defined as an increase in mean pulmonary artery pressure (PAP) of > 25 mmHg with an increase in pulmonary vascular resistance of > 240 dyn.s/cm-5 and a normal pulmonary capillary wedge pressure ( < 15 mmHg), which often occurs in subjects with liver cirrhosis. Histopathological features of PPHT are endothelial and smooth-muscle cell proliferation and fibrosis leading to luminal obstruction in the resistance arteries. The pathogenesis of PPHT may result from an imbalance between vasoconstrictor and vasodilating factors. The most common pulmonary symptom is exertional dyspnea; fatigue, chest pain and syncope occur more often at an advanced stage. Edema, ascites and prominent jugular veins are signs of both decompensated hepatic cirrhosis and right ventricular failure. Right heart catheterisation is the gold standard for the diagnosis and defines PPHT in mild disease with PAP less than 35 mmHg, moderate disease with PAP between 35 and 45 mmHg, and severe disease with PAP of 45 mmHg or higher. The medical treatment of portopulmonary hypertension is based on the treatment of other forms of pulmonary arterial hypertension, including vasomodulating pharmacologic agents. Liver transplantation is accompanied by high risk of mortality, generally due to acute right ventricular failure and cardiovascular collapse. The prognosis of PPHT is poor with mean survival of 15 months.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Lv, Yong, Guohong Han und Daiming Fan. „Portopulmonary hypertension“. Scandinavian Journal of Gastroenterology 51, Nr. 7 (22.03.2016): 795–806. http://dx.doi.org/10.3109/00365521.2016.1157895.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Mukhtar, Nizar A., und Oren K. Fix. „Portopulmonary Hypertension“. Journal of Clinical Gastroenterology 45, Nr. 8 (September 2011): 703–10. http://dx.doi.org/10.1097/mcg.0b013e31820656bd.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Le Pavec, Jérôme, Rogério Souza, Philippe Herve, Didier Lebrec, Laurent Savale, Colas Tcherakian, Xavier Jaïs et al. „Portopulmonary Hypertension“. American Journal of Respiratory and Critical Care Medicine 178, Nr. 6 (15.09.2008): 637–43. http://dx.doi.org/10.1164/rccm.200804-613oc.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Watherald, Jason, Olivier Sitbon und Laurent Savale. „Portopulmonary Hypertension“. Seminars in Respiratory and Critical Care Medicine 38, Nr. 05 (Oktober 2017): 651–61. http://dx.doi.org/10.1055/s-0037-1606251.

Der volle Inhalt der Quelle

Annotation:

AbstractPortal hypertension may have major consequences on the pulmonary vasculature due to complex pathophysiological interactions between liver and lungs. Portopulmonary hypertension (PoPH) is characterized by the association of portal hypertension and pulmonary arterial hypertension (PAH). As progressive elevation of right ventricular afterload can lead to right heart failure, PoPH is a serious complication of portal hypertension, affecting functional status and prognosis of patients. Early detection by transthoracic echocardiography must be performed in symptomatic patients and in candidates for liver transplantation (LT). Right heart catheterization remains mandatory to confirm the diagnosis and exclude all other causes of elevated pulmonary pressures. The management of PoPH includes PAH-targeted therapies although few studies have evaluated these medications in this specific indication. The impact of LT on PoPH outcome remains complex and must be specified by future collaborative investigation. Although uncontrolled PoPH is associated with higher risk of postoperative right heart failure and death, stabilization, improvement, or normalization of pulmonary hemodynamics after LT seem to be achievable goals in selected patients with PoPH.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

DuBrock, Hilary M., Reena J. Salgia, Norman L. Sussman, Sonja D. Bartolome, Zakiyah Kadry, David C. Mulligan, Sarah Jenkins et al. „Portopulmonary Hypertension“. Transplantation Direct 5, Nr. 6 (Juni 2019): e456. http://dx.doi.org/10.1097/txd.0000000000000900.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Sakuma, Masahito, Shinko Souma, Osamu Kitamukai, Jun Demachi, Tohru Takahashi, Jun Suzuki, Jun Nawata et al. „Portopulmonary Hypertension“. Circulation Journal 69, Nr. 11 (2005): 1386–93. http://dx.doi.org/10.1253/circj.69.1386.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Krowka, Michael. „Portopulmonary Hypertension“. Seminars in Respiratory and Critical Care Medicine 33, Nr. 01 (Februar 2012): 17–25. http://dx.doi.org/10.1055/s-0032-1301731.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Sokol, Ronald J. „Portopulmonary Hypertension“. Journal of Pediatric Gastroenterology and Nutrition 61, Nr. 3 (September 2015): 268–69. http://dx.doi.org/10.1097/mpg.0000000000000892.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Budhiraja, Rohit, und Paul M. Hassoun. „Portopulmonary Hypertension*“. Chest 123, Nr. 2 (Februar 2003): 562–76. http://dx.doi.org/10.1378/chest.123.2.562.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Nayak, Ravi P., Dechun Li und George M. Matuschak. „Portopulmonary hypertension“. Current Gastroenterology Reports 11, Nr. 1 (17.01.2009): 56–63. http://dx.doi.org/10.1007/s11894-009-0009-3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Halank, Michael, Ralf Ewert, Hans-Juergen Seyfarth und Gert Hoeffken. „Portopulmonary hypertension“. Journal of Gastroenterology 41, Nr. 9 (16.10.2006): 837–47. http://dx.doi.org/10.1007/s00535-006-1879-x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Halank, Michael, Ralf Ewert, Hans-Juergen Seyfarth und Gert Hoeffken. „Portopulmonary hypertension“. Journal of Gastroenterology 41, Nr. 11 (08.12.2006): 1133. http://dx.doi.org/10.1007/s00535-006-1971-2.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

Passarella, Michael, Michael B. Fallon und Steven M. Kawut. „Portopulmonary Hypertension“. Clinics in Liver Disease 10, Nr. 3 (August 2006): 653–63. http://dx.doi.org/10.1016/j.cld.2006.08.023.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Cartin-Ceba, Rodrigo, und Michael J. Krowka. „Portopulmonary Hypertension“. Clinics in Liver Disease 18, Nr. 2 (Mai 2014): 421–38. http://dx.doi.org/10.1016/j.cld.2014.01.004.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Sitbon, Olivier, Dermot S. O'Callaghan und Laurent Savale. „Portopulmonary Hypertension“. Chest 141, Nr. 4 (April 2012): 840–42. http://dx.doi.org/10.1378/chest.11-2378.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Krowka, Michael J., und Michael D. McGoon. „Portopulmonary Hypertension“. Chest 112, Nr. 4 (Oktober 1997): 869–70. http://dx.doi.org/10.1378/chest.112.4.869.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Krowka, Michael J., Dave P. Miller, Robyn J. Barst, Darren Taichman, Raed A. Dweik, David B. Badesch und Michael D. McGoon. „Portopulmonary Hypertension“. Chest 141, Nr. 4 (April 2012): 906–15. http://dx.doi.org/10.1378/chest.11-0160.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Golbin, Jason M., und Michael J. Krowka. „Portopulmonary Hypertension“. Clinics in Chest Medicine 28, Nr. 1 (März 2007): 203–18. http://dx.doi.org/10.1016/j.ccm.2006.11.004.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Al-Naamani, Nadine, und Kari E. Roberts. „Portopulmonary Hypertension“. Clinics in Chest Medicine 34, Nr. 4 (Dezember 2013): 719–37. http://dx.doi.org/10.1016/j.ccm.2013.08.008.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Wells, J. T., J. R. Runo und M. R. Lucey. „Portopulmonary hypertension“. Hepatology 48, Nr. 1 (Juli 2008): 13–15. http://dx.doi.org/10.1002/hep.22378.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Thévenot, Thierry, Delphine Weil, Marie-France Seronde, Sarah Raevens und Laurent Savale. „Portopulmonary hypertension“. Hépato-Gastro & Oncologie Digestive 30, Nr. 6 (Juni 2023): 605–14. http://dx.doi.org/10.1684/hpg.2023.2601.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Chooklin, S. M., S. S. Chuklin, M. M. Posivnych und S. A. Krystopchuk. „Portopulmonary hypertension: peculiarities of diagnosis and treatment“. EMERGENCY MEDICINE 20, Nr. 3 (17.05.2024): 146–58. http://dx.doi.org/10.22141/2224-0586.20.3.2024.1686.

Der volle Inhalt der Quelle

Annotation:

Portopulmonary hypertension is defined as the development of pulmonary hypertension secondary to portal one. Its exact prevalence is difficult to determine due to the lack of routine screening in patients with portal hypertension. Hemodynamic changes associated with portal hypertension, including the hyperdynamic state, portosystemic shunts, and splanchnic vasodilation, cause significant disturbances in the pulmonary vasculature and play a key role in the pathogenesis of the disease. Without treatment, portopulmonary hypertension leads to progressive right ventricular failure with a poor prognosis. Although Doppler echocardiography is the best initial screening tool for symptomatic patients and candidates for liver transplant, right heart catheterization remains the gold standard for disease diagnosis. Treatment of patients with portopulmonary hypertension is aimed at improving cardiac function, reducing pulmonary vascular resistance, and optimizing functional capacity. Pulmonary hypertension-specific therapy, which includes prostacyclin and its receptor agonists, endothelin receptor antagonists, phosphodiesterase inhibitors, and guanylate cyclase stimulators, plays a key role in the treatment of patients with portopulmonary hypertension. Small uncontrolled and recent single randomized controlled trials have reported promising results of vasodilator therapy in terms of clinical and hemodynamic improvement in patients, allowing certain patients to undergo liver transplantation. This review discusses the epidemiology, approach to diagnosis and treatment of patients with portopulmonary hypertension. We used MEDLINE database on the PubMed platform and the Cochrane library to search for literature sources using the keywords: portopulmonary hypertension, portal hypertension, pulmonary hypertension, liver cirrhosis, pulmonary complications.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Fisher, Jolene H., Sindhu R. Johnson, Cathy Chau, Amie T. Kron und John T. Granton. „Effectiveness of Phosphodiesterase-5 Inhibitor Therapy for Portopulmonary Hypertension“. Canadian Respiratory Journal 22, Nr. 1 (2015): 42–46. http://dx.doi.org/10.1155/2015/810376.

Der volle Inhalt der Quelle

Annotation:

BACKGROUND: Portopulmonary hypertension is associated with significant morbidity and mortality. Phosphodiesterase-5 inhibitor therapy is efficacious in other causes of WHO group I pulmonary arterial hypertension.OBJECTIVE: To evaluate the efficacy and safety of phosphodiesterase-5 inhibitor therapy in patients with portopulmonary hypertension.METHODS: A single-centre retrospective cohort study that included patients with a diagnosis of portopulmonary hypertension was performed. The primary outcome was change in pulmonary vascular resistance after six months of phosphodiesterase-5 inhibitor therapy. A secondary evaluation investigated the effect on other hemodynamic measurements, 6 min walk distance, functional class, safety outcomes and survival.RESULTS: Of 1385 patients screened, 25 patients with portopulmonary hypertension were identified, of whom 20 received a phosphodiesterase-5 inhibitor. After six months, there was a significant decrease in pulmonary vascular resistance (−236 dyn·s·cm−5[95% CI −343 dyn·s·cm−5to −130 dyn·s·cm−5]; P<0.001), mean pulmonary artery pressure (−8.9 mmHg [95% CI −13.7 mmHg to −4.2 mmHg]; P=0.001) and an increase in Fick cardiac output (0.9 L/min [95% CI 0.1 L/min to 1.6 L/min]; P=0.02). There was no change in 6 min walk distance. The proportion of subjects with a WHO functional class III or IV was significantly reduced at six months compared with baseline (18% versus 61%; P=0.002). Safety outcomes did not reveal any adverse events.CONCLUSIONS: Phosphodiesterase-5 inhibitor therapy improved hemodynamics and functional class at six months in a cohort of patients with portopulmonary hypertension.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Gossage, James R. „Primary Pulmonary Hypertension or Portopulmonary Hypertension?“ Chest 114, Nr. 4 (Oktober 1998): 1224–25. http://dx.doi.org/10.1378/chest.114.4.1224-a.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

VV, Potii, Kiriienko VT, Potii DA, Glukhova EI und Kunickaya OS. „Portopulmonary Hypertension (Literature Review)“. Acta Scientific Gastrointestinal Disorders 5, Nr. 1 (01.01.2022): 67–73. http://dx.doi.org/10.31080/asgis.2022.05.0371.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Porres-Aguilar, Mateo, und Debabrata Mukherjee. „Portopulmonary hypertension: An update“. Respirology 20, Nr. 2 (18.12.2014): 235–42. http://dx.doi.org/10.1111/resp.12455.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Stauber, Rudolf E., und Horst Olschewski. „Portopulmonary hypertension: short review“. European Journal of Gastroenterology & Hepatology 22, Nr. 4 (April 2010): 385–90. http://dx.doi.org/10.1097/meg.0b013e3283337130.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Koek, G. „Portopulmonary hypertension; treatment experience“. Journal of Hepatology 34 (April 2001): 54. http://dx.doi.org/10.1016/s0168-8278(01)80181-1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Koek, G. H., F. Yurd, E. Haagsma, A. Boonstra, M. Delcroix und J. Pirenne. „Portopulmonary hypertension; treatment experience“. Journal of Hepatology 34 (April 2001): 54. http://dx.doi.org/10.1016/s0168-8278(01)81056-4.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Maruyama, Toru, Kohichi Ohsaki, Shinji Shimoda, Yoshikazu Kaji und Mine Harada. „Thromboxane-dependent portopulmonary hypertension“. American Journal of Medicine 118, Nr. 1 (Januar 2005): 93–94. http://dx.doi.org/10.1016/j.amjmed.2004.11.007.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Perkins, James D. „Screening for portopulmonary hypertension“. Liver Transplantation 13, Nr. 3 (2007): 463–67. http://dx.doi.org/10.1002/lt.21105.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Safdar, Zeenat, Sonja Bartolome und Norman Sussman. „Portopulmonary hypertension: An update“. Liver Transplantation 18, Nr. 8 (24.07.2012): 881–91. http://dx.doi.org/10.1002/lt.23485.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Ruggiero, Rosechelle M., und Sonja D. Bartolome. „Portopulmonary Hypertension: A Review“. Advances in Pulmonary Hypertension 21, Nr. 4 (01.10.2022): 123–29. http://dx.doi.org/10.21693/1933-088x-21.4.123.

Der volle Inhalt der Quelle

Annotation:

Portopulmonary hypertension (POPH) is a rare complication of liver disease occurring when pulmonary arterial hypertension develops in the setting of portal hypertension. It increases the morbidity and mortality compared to patients with cirrhosis alone. POPH is classified in Group 1 pulmonary arterial hypertension, which has important implications on treatment. After aggressive treatment and in carefully selected patients, liver transplantation can be performed; this can be curative of not only their liver disease but also of their POPH. Treatment and patient selection for optimum results continues to evolve. This article provides updates on the definition, clinical course, and treatment of patients with POPH. We will also discuss the evolving data in treatment and liver transplantation in POPH.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Jasso-Baltazar, Erick A., Gonzalo A. Peña-Arellano, Jonathan Aguirre-Valadez, Isaac Ruiz, Bruno Papacristofilou-Riebeling, Jose Victor Jimenez, Cristian J. García-Carrera et al. „Portopulmonary Hypertension: An Updated Review“. Transplantation Direct 9, Nr. 8 (21.07.2023): e1517. http://dx.doi.org/10.1097/txd.0000000000001517.

Der volle Inhalt der Quelle

Annotation:

Portal hypertension may have major consequences on the pulmonary vasculature due to the complex pathophysiological interactions between the liver and lungs. Portopulmonary hypertension (PoPH), a subset of group 1 pulmonary hypertension (PH), is a serious pulmonary vascular disease secondary to portal hypertension, and is the fourth most common subtype of pulmonary arterial hypertension. It is most commonly observed in cirrhotic patients; however, patients with noncirrhotic portal hypertension can also develop it. On suspicion of PoPH, the initial evaluation is by a transthoracic echocardiogram in which, if elevated pulmonary pressures are shown, patients should undergo right heart catheterization to confirm the diagnosis. The prognosis is extremely poor in untreated patients; therefore, management includes pulmonary arterial hypertension therapies with the aim of improving pulmonary hemodynamics and moving patients to orthotopic liver transplantation (OLT). In this article, we review in detail the epidemiology, pathophysiology, process for diagnosis, and most current treatments including OLT and prognosis in patients with PoPH. In addition, we present a diagnostic algorithm that includes the current criteria to properly select patients with PoPH who are candidates for OLT.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Huang, Li, Wen Li, Tao Yang, Changming Xiong, Xinhai Ni, Qing Gu und Jianguo He. „Association between splenectomy and portal hypertension in the development of pulmonary hypertension“. Pulmonary Circulation 10, Nr. 1 (Januar 2020): 204589401989542. http://dx.doi.org/10.1177/2045894019895426.

Der volle Inhalt der Quelle

Annotation:

Both portal hypertension and splenectomy are risk factors for pulmonary hypertension. However, the interactions between portal hypertension and splenectomy in the development of pulmonary hypertension remain unclear. Twelve newly diagnosed pulmonary hypertension patients with a previous history of splenectomy induced by portal hypertension were recruited between November 2008 and May 2017. We compared their clinical features, hemodynamics, and prognosis with idiopathic pulmonary arterial hypertension patients, who were matched by cardiac index, mean pulmonary arterial pressure, and pulmonary vascular resistance. We also compared the clinical characteristics of portal hypertension-post-splenectomy-pulmonary hypertension patients with eight portopulmonary hypertension patients. Compared with the matched idiopathic pulmonary arterial hypertension patients, the portal hypertension-post-splenectomy-pulmonary hypertension patients showed significantly wider red blood cell distribution width (16.7 ± 2.8% versus 13.3 ± 1.7%, p = 0.004), higher total bilirubin concentration (31.0 ± 13.8 µmol/l versus 18.9 ± 10.0 µmol/l, p = 0.010), and higher lactate dehydrogenase concentration (321.5 ± 41.2 IU/l versus 229.2 ± 69.4 IU/l, p = 0.001). Kaplan–Meier survival analyses showed that the portal hypertension-post-splenectomy-pulmonary hypertension patients tended to have poorer prognosis than the matched idiopathic pulmonary arterial hypertension patients (log-rank test: p = 0.010). Compared with the portal hypertension-post-splenectomy-pulmonary hypertension patients, the portopulmonary hypertension cohort appeared to exhibit poorer clinical conditions, including significantly lower mixed venous oxygen saturation (62.9 ± 8.0% versus 73.9 ± 6.5%, p = 0.004) and a significantly higher proportion of pericardial effusion (75.0% versus 8.3%, p = 0.004), even though the two cohorts showed similar hemodynamics. The mean intervals from diagnosis of portal hypertension to pulmonary hypertension in portopulmonary hypertension patients were significantly shorter than the intervals from splenectomy to diagnosis of pulmonary hypertension in portal hypertension-post-splenectomy-pulmonary hypertension patients (5.5 ± 5.2 years versus 13.1 ± 5.9 years, p = 0.008). Splenectomy might be involved in the initiation and development of pulmonary hypertension in patients with portal hypertension, although the precise mechanisms involved remain unknown. Portal hypertension-post-splenectomy-pulmonary hypertension patients might have poorer prognosis even with mild hemodynamics.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Akahane, Takemi. „Factors associated with portopulmonary hypertension“. Hepatology Research 51, Nr. 12 (30.11.2021): 1179–80. http://dx.doi.org/10.1111/hepr.13721.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Restrepo, Ricardo, Esmé F. Singer und Michael Baram. „Hepatopulmonary Syndrome and Portopulmonary Hypertension“. Hospital Practice 41, Nr. 2 (April 2013): 62–71. http://dx.doi.org/10.3810/hp.2013.04.1049.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Aldenkortt, Florence. „Portopulmonary hypertension and hepatopulmonary syndrome“. World Journal of Gastroenterology 20, Nr. 25 (2014): 8072. http://dx.doi.org/10.3748/wjg.v20.i25.8072.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Auzinger, Georg, und Julia A. Wendon. „Hepatopulmonary Syndrome and Portopulmonary Hypertension“. Critical Care Medicine 33, Nr. 2 (Februar 2005): 470–71. http://dx.doi.org/10.1097/01.ccm.0000153598.84976.e9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Wiklund, Richard A. „Hepatopulmonary Syndrome and Portopulmonary Hypertension“. Critical Care Medicine 33, Nr. 2 (Februar 2005): 471. http://dx.doi.org/10.1097/01.ccm.0000153601.32819.b0.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Hoeper, M. M. „Bosentan therapy for portopulmonary hypertension“. European Respiratory Journal 25, Nr. 3 (01.03.2005): 502–8. http://dx.doi.org/10.1183/09031936.05.00080804.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Reichenberger, F., R. Voswinckel, E. Steveling, B. Enke, A. Kreckel, H. Olschewski, F. Grimminger, W. Seeger und H. A. Ghofrani. „Sildenafil treatment for portopulmonary hypertension“. European Respiratory Journal 28, Nr. 3 (28.06.2006): 563–67. http://dx.doi.org/10.1183/09031936.06.00030206.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Ioachimescu, O. C., A. C. Mehta und J. K. Stoller. „Hepatopulmonary syndrome following portopulmonary hypertension“. European Respiratory Journal 29, Nr. 6 (01.03.2007): 1277–80. http://dx.doi.org/10.1183/09031936.00140306.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

KAMATH, PATRICK S. „Portopulmonary hypertension and hepatopulmonary syndrome“. Journal of Gastroenterology and Hepatology 17 (Dezember 2002): S253—S255. http://dx.doi.org/10.1046/j.1440-1746.17.s3.9.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Fuhrmann, Valentin, und Daniel Benten. „Hepatopulmonales Syndrom und portopulmonale Hypertension“. Gastroenterologie up2date 11, Nr. 01 (10.03.2015): 27–38. http://dx.doi.org/10.1055/s-0034-1391648.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!